You have been saying that for six months to no avail. I how you are short the stock. One thing you have going for you is that you can always shear the goats and make your own cloths and you won't have to wear a barrel and suspenders. t
Blood, I think that there is a lot of cross-currents that are variables that have to be taken into consideration. I am very happy that RNN got three posters at ASCO. Relatively speaking they did excellent, but the communication in this regard is more one on one compared to a presentation. The other thing we to hope for is that these drugs get that WOW factor from wall street like the CAR-T1 drugs do. I think they will. Already we are seeing that most probably CAR-T1 drugs won't be as useful for solid tumors as originally hoped. They appear excellent for blood cancers, but not so good for solid cancers. The incredible thing about these drugs is their low toxicity. But that variable is one thing the other side that will hard to grasp by cancer experts is that they are then thus still effective in fighting CA if the drugs are that "mild?" The company that comes closest to this one that has had excellent success is PCYC. They have only one drug, but that drug is a pipeline in a drug. It too is being used as a second-line agent in the more fragile, more elderly patient. That is where these drugs could really fit in. If they have tremendous efficacy and that safety they could be considered first line in some CA's. Obviously, each drug will not work equally well on all of the different types of CA's. Why I point out always what the competition is doing is for us to have a measuring stick for these RNN drugs to go against. I think that there is a good chance that the CAR-T1 inhibitors and the Checkpoint inhibitors will disappoint a little bit based on how much hype they have already received, and that these three drugs will surprise to the upside. Once really good news does come out, if it does, then the company has to do a much better job of promoting the goods. What would also be nice would be to let potential investors know more about their potential pipeline so as to help further value the company. t
Jetman, just one last question with regard to your posting above, how much do you think the Amgens & Mercks of th,is world might be willing to put on the table if they were to establish interest in RNN's science platform?
I know its pure guesswork, but what do you reckon big pharma mighht be willing to pay for such an acquiisition?
Sentiment: Strong Buy
Guys, love your bullish sentiment, but I was really dissapointed in Fridays reaction to the strong data herdline....maybe this will turn into a slow motion reaction to same as ASCO draws to a close!
RNN, long & strong!
Sentiment: Strong Buy
Hi jetman, you know one thing amazes me, the strong data article really does show which potential "is hidden" within RNN's core science, but this still isn't getting recognised by the marketplace in general.
I am long -and will remain long- but I truly hope that the ASCO platform wakes up the investment community to RNN's fantastic underlying potential, but at the same time, this is why a lot of investors are in the market in the first place, lokking for drastically undervalued stock issues that have 'valid potential' of exploding valuations when their market/competition/investors finally wake up to the issues ongoing potential.
That's why i'm here and will remain here:- RNN to go " public" at ASCO!
Sentiment: Strong Buy
Amgen and Merck (MRK) expand their collaboration to evaluate the efficacy and safety of talimogene laherparepvec in combination with KEYTRUDA (157.35)
The co and Merck (MRK) announced an expanded collaboration to evaluate the efficacy and safety of talimogene laherparepvec, Amgen's investigational oncolytic immunotherapy, in combination with KEYTRUDA (pembrolizumab), Merck's anti-PD-1 therapy, in a Phase 1, open-label trial of patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
In addition, the companies announced that a global, randomized Phase 3 trial evaluating the combination in patients with regionally or distantly metastatic melanoma is being initiated. As previously announced, the compounds are being studied in a Phase 1, open-label trial in this patient population.
This trend will help RNN IMO. t
Sorry...I don't go on any message board with alias's....never have. I have answered myself once...b/c I was bored.
Same name always....no games.
When posters start developing alternate alias's ....herderGoat....herderQoat. It takes very creative...and small minds to waste their time doing that #$%$. But hey....you guys are bored and you need to have some fun since your stock isn't giving you any.